|
Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma Clinical research trials and Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma. Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma clinical trial. Participants frequently obtain the most expert healthcare available for their Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma  Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma
Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma
For Condition: Lymphoma, Mixed-Cell, Follicular,Lymphoma, Small Cleaved-Cell, Follicular,Lymphoma, Follicular,Lymphoma, Low-Grade
Status: Recruiting
Sponsor(s): Novuspharma ,
Synopsis: The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients’ remission, compared to rituximab alone.
Details: This trial is being conducted in patients with indolent (or low-grade) non-Hodgkin’s lymphoma, who have either relapsed or been refractory to previous treatment. Pixantrone belongs to the DNA intercalator family of chemotherapy agents, which includes anthracyclines. DNA intercalators are commonly used to treat patients with indolent NHL, often in combination with the monoclonal antibody rituximab. This study represents the first large-scale, comparative trial in indolent NHL, designed to determine whether the response rate and time to tumour progression in patients treated with a combination of rituximab and a DNA intercalator, is significantly higher than seen in patients treated with rituximab alone. This trial is randomized and controlled, which means that participating patients will be randomly assigned to one of two treatment groups: 1) Patients treated with both pixantrone and rituximab, in combination 2) Patients treated with only rituximab This trial is expected to recruit around 800 patients in the US, Europe and Israel, with 400 patients recruited to each group. Patients will be treated for around 18 weeks and will recieve regular physician monitoring for five years from the end of treatment.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL), including follicular lymphoma grade I and II - Presenting with an episode of progressive disease, following 1-5 prior treatments (with either radiation, chemotherapy or rituximab). Exclusion criteria: - Patients that failed to respond to previous rituximab treatment, or relapsed within 6 months of the first rituximab infusion - Patients known to have an allergic reaction to rituximab or murine derived proteins.
Total Enrollment: 800
Location and Contact Information:
New Mexico Oncology / Hematology *Recruiting*
Albuquerque, New Mexico, 87109
United States
Recruiting Debra Harris 505-243-4039
Oncology of Wisconsin *Recruiting*
Glendale, Wisconsin, 53212
United States
Recruiting Tammy Leischer 414-906-4400
St. Johns Mercy Medical Center *Recruiting*
St. Louis, Missouri, 63141
United States
Recruiting Christy Hill 314-569-6933
Hope Center *Recruiting*
Terre Haute, Indiana, 47802
United States
Recruiting Jacquelyn Bradfield 812-234-0098
Great Falls Clinic *Recruiting*
Great Falls, Montana, 59405
United States
Recruiting Bernadette Mundt 406-452-6657
Hematology - Oncology Centers of N. Rockies *Recruiting*
Billings, Montana, 59101
United States
Recruiting Mary Zandt 406-238-6962
Pasco, Hernando Oncology Associates, P.A. *Recruiting*
New Port Richey, Florida,
United States
Recruiting Eve Crosariol 727-842-2795
New York University *Recruiting*
New York City, New York, 10016
United States
Recruiting Elena DeFrancisco
Sutter Health Western Division Cancer Research Group *Recruiting*
Greenbrae, California, 94904
United States
Recruiting Lyssa Friedman 415-925-7916
Clinworks, Inc *Recruiting*
Charlotte, North Carolina,
United States
Recruiting Terri Carpenter 704-367-9334
Central Utah Medical Clinic Hematology-Oncology *Recruiting*
Provo, Utah, 84604
United States
Recruiting Yolonda Stock 801-429-8024
Commonwealth Hematology/Oncology *Recruiting*
Danville, Kentucky, 40422
United States
Recruiting Julie Jones 859-236-2203
Glens Falls Cancer Center *Recruiting*
Glen Falls, New York, 12801
United States
Recruiting Josephine Barilli 518-926-6649
Hematology Oncology Associates of NJ *Recruiting*
Paramus, New Jersey, 07652
United States
Recruiting Jessica Bird 201-634-5353
Rhinelander Regional Medical Group Onc. *Recruiting*
Rhinelander, Wisconsin, 54501
United States
Recruiting Nancy Carl 715-361-4714
University of Chicago Medical Center Hematology / Oncology *Not yet recruiting*
Chicago, Illinois, 60637
United States
Not yet recruiting Kathy Atwater 773-702-2034
HemOnCare, P.C. *Recruiting*
Brooklyn, New York, 11235
United States
Recruiting Lois Helgeson 718-616-0801
Lancaster Cancer Center, LTD *Recruiting*
Lancaster, Pennsylvania, 17605
United States
Recruiting Barbara Groff 717-291-1313
Illinois Masonic Cancer Center *Not yet recruiting*
Chicago, Illinois, 60657
United States
Not yet recruiting Ken Ziganto 773-296-5360
North Shore - Long Island Jewish Health System *Recruiting*
New Hyde Park, New York, 11040
United States
Recruiting Dale Janson 718-470-4408
Orange Park Cancer Center *Recruiting*
Orange Park, Florida, 32073
United States
Recruiting Carla Malott 904-272-3139
Arizona Clinical Research Center *Not yet recruiting*
Tucson, Arizona, 85712
United States
Not yet recruiting Patricia Plezia 520-290-2510
Kenmar Research Institute *Recruiting*
Los Angeles, California, 90057
United States
Recruiting Anne Kennedy 213-386-1888
Marshfield Clinic *Recruiting*
Marshfield, Wisconsin, 54449
United States
Recruiting Anita Lyrenmann 715-387-5903
East Orange VA Medical Center *Recruiting*
East Orange, New Jersey, 07018
United States
Recruiting Xianwen Qiau 973-395-7087
Edward Cancer Center *Recruiting*
Naperville, Illinois, 60540
United States
Recruiting Kathy Seymour 630-527-3787
Private Practice *Recruiting*
Canton, Ohio, 44718
United States
Recruiting Carrie Smith 330-492-3345
The West Clinic *Not yet recruiting*
Memphis, Tennessee, 38120
United States
Not yet recruiting Jeri Ashley 901-683-0055
Ocala Oncology Center *Recruiting*
Ocala, Florida, 34474
United States
Recruiting Renee Genther 352-732-4938
Blair Medical Associates *Recruiting*
Altoona, Pennsylvania, 16601
United States
Recruiting Robin Stern 814-947-6177
South Shore Hematology-Oncology Associates *Recruiting*
Rockville Centre, New York, 11570
United States
Recruiting Jeanne Davy 516-536-1455
Christian Hospital *Recruiting*
St. Louis, Missouri, 63136
United States
Recruiting Hellen Mullner 314-355-5597
New England Hematology / Oncology Associates *Recruiting*
Wellesley, Massachusetts, 02481
United States
Recruiting Eileen Capstraw 781-237-5591
Summit Medical Group/Overlook Onc Center *Recruiting*
Summit, New Jersey, 07901
United States
Recruiting Vanessa DePaul 908-273-4300
Santee Hematology Oncology *Recruiting*
Sumter, South Carolina, 29150
United States
Recruiting Sunil Sharma 803-934-8833
Rocky Moutain Cancer Center *Not yet recruiting*
Denver, Colorado, 80218
United States
Not yet recruiting Joni Newman 303-388-4876
Upstate NY Cancer Research *Recruiting*
Rochester, New York, 14623
United States
Recruiting Sue-Ellen Sahmel 585-350-2300
St. Joseph Oncology *Recruiting*
St. Joseph, Missouri, 64507
United States
Recruiting Bob Moore 816-271-1032
Additional Information:
Study ID Numbers: AZA III 02;
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00060671
Other Lymphoma, Small Cleaved-Cell, Follicular Studies:
1. Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma
2. Dose ranging trial for pixantrone in the FND-R variant regimen in indolent non-Hodgkin's lymphoma
Related Studies:
Other Lymphoma, Small Cleaved-Cell, Follicular Clinical Trials
Other Pennsylvania Clinical Trials
Other Lancaster Clinical Trials
Comparative trial for pixantrone in combination with rituximab in indolent non-Hodgkin's lymphoma
|
|
|
|
|
|
|
|
